Long-term multicentre trial with TA-RO CAP, a new spermicidal product.
326 healthy couples were selected to enter the trial of a new intravaginal contraceptive called the TA-RO CAP. The trial lasted three years. Clinical and laboratory examinations were performed periodically to determine the long-term effectiveness, tolerability and acceptance. Statistical evaluation of results was performed by life-table analysis.
D000206:Actuarial Analysis; D000328:Adult; D001558:Benzethonium / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D017137:Nonoxynol; D011092:Polyethylene Glycols / Q000494:pharmacology*; D011247:Pregnancy; D000644:Quaternary Ammonium Compounds / Q000494:pharmacology*; D013089:Spermatocidal Agents / Q000494:pharmacology*; D013997:Time Factors; D014621:Vagina; D014622:Vaginal Creams, Foams, and Jellies / Q000494:pharmacology*
D004338:Drug Combinations; D000644:Quaternary Ammonium Compounds; D013089:Spermatocidal Agents; D014622:Vaginal Creams, Foams, and Jellies; D001558:Benzethonium; D017137:Nonoxynol; D011092:Polyethylene Glycols; C024156:TA-RO CAP